

Creating a future where vascular diseases no longer limit life's potential.

WHAT DRIVES US

With increasing life expectancy, aging-related diseases are on the rise, while effective treatments remain limited. Our mission is to promote healthy aging by developing innovative therapies that enhance local blood circulation, targeting chronic wounds, alopecia, and cancer.

TECHNOLOGY

Unique technology-platform with small molecules leading to unprecedented cGMP increase. Proven effects on:

- Blood circulation
- Cancer signaling
- Fibrosis

KEY FACTS



Founded: 2015



3 Assets in Clinical/Preclinical Programs



Intellectual Property: Strong IP Protection



Numerous Industry Awards



Investment Opportunity:

- \$23M Capital Increase
- **\$5M** Convertible Bonds

MANAGEMENT TEAM

CEO & Founder: Dr. Reto Naef CIO & Deputy CEO: PD Dr. Matthias Schäfer

CFO a.i.: Cornelia Gehrig

BOARD OF DIRECTORS

Dr. Reto Naef (President)

Dr. Daniel L. Vasella (Vice President)

Dr. Dominik Escher

Silvia Scherer

Prof. Dr. Grünther Wess

Cornelia Gehrig

Pascal Brenneisen

USPs

- **High-Value Pipeline:** Novel dual-mode of action drugs enabling blood circulation for multiple indications with large, unmet market needs
- **Robust Patent Portfolio:** Composition and formulation patents extending protection into the 2040s
- **Orphan Drug Advantage:** Accelerated market access and extended exclusivity for digital ulcer therapy
- **Strategic Partnerships:** Partnerships lined up for broader indications with substantial exit opportunities

PIPELINE

	Preclinical Discovery	Toxicology	Clinical Phase I	Phase II	Phase III
TOP-N53	Digital Ulcer in Systemic Sclerosis (DU)				
	Diabetic Foot Ulcer (DFU)				
TOP-M119	Alopecia (Rx and OTC) Financed Co-development - Oshen Holdings SA				
TOP-V122	Portfolio Assets				

BUSINESS CASE

MARKET SIZE

Systemic Sclerosis: Diabetic Foot Ulcer: Alopecia:

\$ 2.9B p.a. **\$ 8.2B** p.a. **\$ 8.8B** p.a.

6.4% CAGR 5.9% CAGR 9.1% CAGR

REVENUE PROJECTION

Digital Ulcer: Diabetic Foot Ulcer: Alopecia:

> \$ 1B _{p.a.} > \$ 1B _{p.a.} > \$ 2B _{p.a.}

Join us to deliver breakthrough solutions that address the most pressing unmet medical needs in aging-related diseases.

TOPADUR PHARMA AG

+41 44 755 44 66 | info@topadur.com www.topadur.com https://www.linkedin.com/company/topadur



